Mattia Francesco Maria Gerli

Dr. Mattia Francesco Maria Gerli

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco
MGMattia Francesco Maria Gerli
Mattia Francesco Maria Gerli
LPLaura Perani
Laura Perani
SBSara Benedetti
Sara Benedetti
FUFederica Ungaro
Federica Ungaro
GCGiulio Cossu
Giulio Cossu
Genetically corrected mesoangioblasts from human iPSCs derived from limb-girdle muscular dystrophy patients produce muscle fibers expressing the therapeutic gene in a mouse model of the disease.

3 February 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen
RCRob P. Coppes
Rob P. Coppes
ABAnne Beghin
Anne Beghin
PCPaolo De Coppi
Paolo De Coppi
MGMattia Francesco Maria Gerli
Mattia Francesco Maria Gerli
Luc J.W. van der LaanLuc J.W. van der Laan
Luc J.W. van der Laan

3 October 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
BSBruno Di Stefano
Bruno Di Stefano
ELEn-Ching Luo
En-Ching Luo
CHChuck Haggerty
Chuck Haggerty
SAStefan Aigner
Stefan Aigner
JCJocelyn Charlton
Jocelyn Charlton
KHKonrad Hochedlinger
Konrad Hochedlinger

17 August 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco
HHHidetoshi Hoshiya
Hidetoshi Hoshiya
Giuseppe D'AntonaGiuseppe D'Antona
Giuseppe D'Antona
MGMattia Francesco Maria Gerli
Mattia Francesco Maria Gerli
Messina GraziellaMessina Graziella
Messina Graziella
GCGiulio Cossu
Giulio Cossu
Combining gene delivery using a human artificial chromosome with stem cell transplantation ameliorates muscular dystrophy in a mouse model.

4 June 2015 in Nature Protocols
Verified
Journal Article
Closed access
SMSara M Maffioletti
Sara M Maffioletti
MGMattia Francesco Maria Gerli
Mattia Francesco Maria Gerli
MRMartina Ragazzi
Martina Ragazzi
SDSumitava Dastidar
Sumitava Dastidar
SBSara Benedetti
Sara Benedetti
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco

27 June 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
SDSumitava Dastidar
Sumitava Dastidar
SASimon Ardui
Simon Ardui
KSKshitiz Singh
Kshitiz Singh
DMDebanjana Majumdar
Debanjana Majumdar
NNNisha Nair
Nisha Nair
TVThierry VandenDriessche
Thierry VandenDriessche
CRISPR/Cas9 is an attractive platform to potentially correct dominant genetic diseases by gene editing with unprecedented precision. In the current proof-of-principle study, we explored the use of CRISPR/Cas9 for gene-editing in myotonic dystrophy type-1 (DM1), an autosomal-dominant muscle disorder, by excising the CTG-repeat expansion in the 3'-untranslated-region (UTR) of the human myotonic dystrophy protein kinase (DMPK) gene in DM1 patient-specific induced pluripotent stem cells (DM1-iPSC), DM1-iPSC-derived myogenic cells and DM1 patient-specific myoblasts. To eliminate the pathogenic gain-of-function mutant DMPK transcript, we designed a dual guide RNA based strategy that excises the CTG-repeat expansion with high efficiency, as confirmed by Southern blot and single molecule real-time (SMRT) sequencing. Correction efficiencies up to 90% could be attained in DM1-iPSC as confirmed at the clonal level, following ribonucleoprotein (RNP) transfection of CRISPR/Cas9 components without the need for selective enrichment. Expanded CTG repeat excision resulted in the disappearance of ribonuclear foci, a quintessential cellular phenotype of DM1, in the corrected DM1-iPSC, DM1-iPSC-derived myogenic cells and DM1 myoblasts. Consequently, the normal intracellular localization of the muscleblind-like splicing regulator 1 (MBNL1) was restored, resulting in the normalization of splicing pattern of SERCA1. This study validates the use of CRISPR/Cas9 for gene editing of repeat expansions.